Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer

Abstract The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive bre...

Full description

Bibliographic Details
Main Authors: Hanne Vos, Kathleen Lambein, François Richard, Bram Mariën, Ines Nevelsteen, Kevin Punie, Hans Wildiers, Lieze Berben, Annouschka Laenen, Giuseppe Floris, Christine Desmedt, Ann Smeets
Format: Article
Language:English
Published: Nature Publishing Group 2021-09-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-021-00332-7
id doaj-8c78a70e9b4d4db798014a17106372d6
record_format Article
spelling doaj-8c78a70e9b4d4db798014a17106372d62021-09-26T11:41:06ZengNature Publishing Groupnpj Breast Cancer2374-46772021-09-01711510.1038/s41523-021-00332-7Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancerHanne Vos0Kathleen Lambein1François Richard2Bram Mariën3Ines Nevelsteen4Kevin Punie5Hans Wildiers6Lieze Berben7Annouschka Laenen8Giuseppe Floris9Christine Desmedt10Ann Smeets11Department of Surgical Oncology, University Hospitals Leuven; Department of Oncology, KU LeuvenDepartment of Surgical Oncology, University Hospitals Leuven; Department of Oncology, KU LeuvenLaboratory for Translational Breast Cancer Research, Department of Oncology, KU LeuvenDepartment of Surgical Oncology, University Hospitals Leuven; Department of Oncology, KU LeuvenDepartment of Surgical Oncology, University Hospitals Leuven; Department of Oncology, KU LeuvenMultidisciplinary Breast Centre, University Hospitals LeuvenMultidisciplinary Breast Centre, University Hospitals LeuvenLaboratory of Experimental Oncology, Department of General Medical Oncology, University Hospitals Leuven, KU LeuvenLeuven Biostatistics and Statistical Bioinformatics Centre (L-BioStat), KU LeuvenMultidisciplinary Breast Centre, University Hospitals LeuvenLaboratory for Translational Breast Cancer Research, Department of Oncology, KU LeuvenDepartment of Surgical Oncology, University Hospitals Leuven; Department of Oncology, KU LeuvenAbstract The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast cancer based on a selection of immune markers at the protein level in an institutional retrospective series. Additionally, we performed a similar comparison using publicly available transcriptomics data. Altogether, the results show a comparable TIME in both groups, with possible implications for the use of ICI in patients with hormone receptor-negative HER2-positive breast tumors.https://doi.org/10.1038/s41523-021-00332-7
collection DOAJ
language English
format Article
sources DOAJ
author Hanne Vos
Kathleen Lambein
François Richard
Bram Mariën
Ines Nevelsteen
Kevin Punie
Hans Wildiers
Lieze Berben
Annouschka Laenen
Giuseppe Floris
Christine Desmedt
Ann Smeets
spellingShingle Hanne Vos
Kathleen Lambein
François Richard
Bram Mariën
Ines Nevelsteen
Kevin Punie
Hans Wildiers
Lieze Berben
Annouschka Laenen
Giuseppe Floris
Christine Desmedt
Ann Smeets
Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
npj Breast Cancer
author_facet Hanne Vos
Kathleen Lambein
François Richard
Bram Mariën
Ines Nevelsteen
Kevin Punie
Hans Wildiers
Lieze Berben
Annouschka Laenen
Giuseppe Floris
Christine Desmedt
Ann Smeets
author_sort Hanne Vos
title Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
title_short Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
title_full Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
title_fullStr Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
title_full_unstemmed Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
title_sort comparison of the tumor immune microenvironment of primary hormone receptor-negative her2-positive and triple negative breast cancer
publisher Nature Publishing Group
series npj Breast Cancer
issn 2374-4677
publishDate 2021-09-01
description Abstract The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast cancer based on a selection of immune markers at the protein level in an institutional retrospective series. Additionally, we performed a similar comparison using publicly available transcriptomics data. Altogether, the results show a comparable TIME in both groups, with possible implications for the use of ICI in patients with hormone receptor-negative HER2-positive breast tumors.
url https://doi.org/10.1038/s41523-021-00332-7
work_keys_str_mv AT hannevos comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT kathleenlambein comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT francoisrichard comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT brammarien comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT inesnevelsteen comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT kevinpunie comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT hanswildiers comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT liezeberben comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT annouschkalaenen comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT giuseppefloris comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT christinedesmedt comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT annsmeets comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
_version_ 1716867787701354496

Similar Items